Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

In recent decades, technical advances in surgery and radiotherapy, as well as
breakthroughs in the knowledge on cancer biology, have helped to substantially improve the …

The current study discovered fifteen new thieno [2, 3-d] pyrimidine derivatives with potential
anticancer action, including 5a-l, 6, and 7a-b. Results from the NCI screening revealed that …

Background: Small cell lung cancer (SCLC) is an extremely aggressive cancer type with a
patient median survival of 6-12 months. Epidermal growth factor (EGF) signaling plays an …

Epidermal growth factor receptor (EGFR), also known as ErbB-1/HER-1, plays a key role in
the regulation of the cell proliferation, migration, differentiation, and survival. Since the …

Lung cancer is the second most common malignant tumor and the leading cause of cancer
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …

It is less known about mi RNA 3127‐5p induced up‐regulation of PD‐L1, immune escape
and drug resistance caused by increased PD‐L1 in lung cancer. In this study, lentivirus was …

The research and treatment of non-small cell lung cancer (NSCLC) have achieved some
important advances in recent years. Nonetheless, the overall survival rates for NSCLC …

Introduction The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET)
is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in …

Lung cancer remains the leading cause of cancer related death worldwide. Despite broad
advances in diagnostics and therapy, the five-year overall survival for patients with …